Davey, CG, Chanen, AM, Hetrick, SE, Cotton, SM, Ratheesh, A, Amminger, GP, Koutsogiannis, J, Phelan, M, Mullen, E, Harrison, BJ, Rice, S, Parker, Alexandra ORCID: 0000-0002-2398-6306, Dean, OM, Weller, A, Kerr, M, Quinn, AL, Catania, L, Kazantzis, N, McGorry, PD and Berk, M (2019) The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. The Lancet Psychiatry, 6 (9). pp. 735-744. ISSN 2215-0366

Rice, SM, Hickie, IB, Yung, AR, Mackinnon, A, Berk, M, Davey, C, Hermens, DF, Hetrick, SE, Parker, Alexandra ORCID: 0000-0002-2398-6306, Schäfer, MR, McGorry, PD and Amminger, GP (2016) Youth depression alleviation: the Fish Oil Youth Depression Study (YoDA-F): A randomized, double-blind, placebo-controlled treatment trial. Early Intervention in Psychiatry, 10 (4). 290 - 299. ISSN 1751-7885

Fernandes, BS, Dash, Sarah ORCID: 0000-0002-7694-3027, Jacka, F, Dodd, S, Carvalho, AF, Köhler, CA, Steiner, J, da Graça Cantarelli, M, Nardin, P, Gonçalves, CA and Berk, M (2016) Leptin in bipolar disorder: a systematic review and meta-analysis. European Psychiatry, 35. pp. 1-7. ISSN 0924-9338

Davey, CG, Chanen, AM, Cotton, SM, Hetrick, SE, Kerr, MJ, Berk, M, Dean, OM, Yuen, K, Phelan, M, Ratheesh, A, Schaefer, MR, Amminger, GP, Parker, Alexandra ORCID: 0000-0002-2398-6306, Piskulic, D, Harrigan, S, Mackinnon, AJ, Harrison, B and McGorry, PD (2014) The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial. Trials, 15 (1). ISSN 1745-6215

Hayley, Amie, Williams, LJ, Kennedy, Gerard, Berk, M, Brennan, SL and Pasco, JA (2014) Prevalence of excessive daytime sleepiness in a sample of the Australian adult population. Sleep Medicine, 15 (3). 348 - 354. ISSN 1389-9457

Francey, SM, Nelson, B, Thompson, A, Parker, Alexandra ORCID: 0000-0002-2398-6306, Kerr, M, Macneil, C, Fraser, R, Hughes, F, Crisp, K, Harrigan, S, Wood, SJ, Berk, M and McGorry, PD (2010) Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophrenia Research, 119 (1-3). ISSN 0920-9964